Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Michael Wang(St. Joseph Health System), Nirav N. Shah(Medical College of Wisconsin), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Kami J. Maddocks(The Ohio State University), Donald E. Tsai(University of Pennsylvania), Koji Izutsu(Tokyo National Hospital), Binoj C. Nair(Eli Lilly (United States)), Constantine S. Tam(The Alfred Hospital), Krish Patel, James N. Gerson(UPMC Hillman Cancer Center), Talha Munir(St James's University Hospital), Youngil Koh(Seoul National University), Toby A. Eyre(Oxford University Hospitals NHS Trust), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Paolo Abada(Eli Lilly (United States)), Junjie Zhao(Loxo Oncology at Lilly (United States)), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Chan Y. Cheah(The University of Western Australia), Timothy S. Fenske(Medical College of Wisconsin), Benoît Tessoulin(Centre Hospitalier Universitaire de Nantes), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), John F. Seymour(The Royal Melbourne Hospital), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Minna Balbas(Roswell Park Comprehensive Cancer Center), Alvaro J. Alencar(University of Miami), Anita Kumar(Memorial Sloan Kettering Cancer Center), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Hirokazu Nagai(Tokai University), Wojciech Jurczak(Jagiellonian University), David Lewis(University Hospitals Plymouth NHS Trust), Yucai Wang(Mayo Clinic), Ian W. Flinn(Tennessee Oncology), Chunxiao Wang(Eli Lilly (United States)), Richard A. Walgren(Eli Lilly (United States))
Cited by 106
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k